pharmaceutical or biopharmaceutical; principal mode of action is chemical rather than structural, like a device.
The global market for coronary stents is estimated to be in excess of $7 billion and projected to be growing at 6% per year. With the average age of citizens in developed countries increasing, there is an increased need to provide medical care to the average citizen. As such, an aging population translates into increasing [...]
The number of competitors developing and marketing cell therapy and tissue engineering products is extraordinary. But since approved clinical applications are proliferating and the resulting market has been driving dramatic double-digit-plus growth, it's unsurprising that competitors from extreme sides of the medical technology industry — drug, device, and biotech — are converging on this lucrative [...]
Options for drug-eluting stent (DES) manufacturers to differentiate their products include stent material, stent shape, drug-deposition methods and others, but most importantly the drug itself. The first drug employed in drug-eluting stents was sirolimus in J&J's CYPHER stent, followed by Boston Scientific with its paclitaxel-coated TAXUS stent.
Since then (2003), the options for drug coatings have [...]
In medical technology development, there are perennially long-shot technologies being pursued for their ability to make an order of magnitude shift in treatment. This, of course, seems to be the thrust of a majority of biotechnology development, which seeks to provide cures where only palliative treatments (drug or device) currently exist, such as in gene [...]
A steady rate of technology development in coronary stents, producing an equally steady stream of new stent market introductions, is focused on expanding aggregate stent caseload (through penetration of what would otherwise be coronary artery bypass caseload) or shifting the balance even further toward concentration of stents sales to the drug-eluting stent (DES) variety. While [...]
Market drivers that vary geographically account for some big differences in the distribution of the coronary stent market across the currently available stent types, and these differences will continue when bioabsorbable stents (and others) are introduced to the market over the next few years.
The local market forces dictating these differences include:
Regulatory timelines in one market [...]
In treatment of acute and chronic wounds, the advanced wound technologies developed by manufacturers provide benefits that facilitate healing, minimize infection and provide other benefits toward reduced cost, less pain, faster healing and combinations of these and other benefits. Advanced products in wound care include film dressings, hydrocolloids, foam dressings, alginate dressings, hydrogels, non-adherent dressings, [...]
PRLog (Press Release) – Sep 09, 2009 – The global market for coronary stents is owned largely by drug-eluting stents (DES), but the size of the patient pool, the drive for lowered cost, ever-increased efficacy and less trauma are spawning the development of multiple new technologies in coronary stents and competitive anti-restenosis technologies. The global [...]
In my regular review of industry press releases, patents (and applications), peer-reviewed journals and other medtech sources, I am occasionally struck by an article or paper that I find compellingly succinct or clear or detailed — or all of the above. The clinical background and technology development of coronary drug-eluting stents are areas I [...]
The global coronary stent market faces continued growth, development and competition from a wide range of technology types and competitors. The market is detailed in a new report from MedMarket Diligence.
FOR IMMEDIATE RELEASE
PRLog (Press Release) – Aug 31, 2009 – Since the advent of coronary stents, followed by the emergence of drug eluting stents, the [...]
Contact:
